Provectus Biopharmaceuticals, Inc.
PVCT
$0.0799
-$0.0024-2.92%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -77.45% | 17.01% | -88.19% | 57.39% | 57.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -77.45% | 17.01% | -88.19% | 57.39% | 57.60% |
| Cost of Revenue | 88.77% | -30.40% | 34.53% | 18.33% | 11.03% |
| Gross Profit | -300.70% | 66.98% | -86.42% | -8.32% | 19.35% |
| SG&A Expenses | 94.74% | 2,372.47% | 727.19% | 24.34% | 15.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 91.74% | 146.90% | 270.09% | 21.44% | 13.19% |
| Operating Income | -158.22% | -261.28% | -357.47% | -17.54% | -1.92% |
| Income Before Tax | -118.72% | -130.48% | -261.31% | -30.76% | -1.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -118.72% | -130.48% | -261.31% | -30.76% | -1.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -114.27% | -126.21% | -261.31% | -30.76% | -1.40% |
| EBIT | -158.22% | -261.28% | -357.47% | -17.54% | -1.92% |
| EBITDA | -159.02% | -264.09% | -359.43% | -17.60% | -1.92% |
| EPS Basic | -115.00% | -125.00% | -256.25% | -33.33% | 0.00% |
| Normalized Basic EPS | -127.27% | -200.00% | -337.50% | -20.00% | -10.00% |
| EPS Diluted | -115.00% | -125.00% | -256.25% | -33.33% | 0.00% |
| Normalized Diluted EPS | -127.27% | -200.00% | -337.50% | -20.00% | -10.00% |
| Average Basic Shares Outstanding | 0.18% | 0.18% | 0.18% | 0.09% | 0.01% |
| Average Diluted Shares Outstanding | 0.18% | 0.18% | 0.18% | 0.09% | 0.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |